An Exploratory Open-Label, Single Dose, Randomized, Three-Way Crossover Study In Healthy Subjects to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2017
At a glance
- Drugs JNJ 54416076 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 18 Dec 2017 Planned End Date changed from 1 Feb 2017 to 17 Feb 2017.
- 18 Dec 2017 Planned primary completion date changed from 1 Feb 2017 to 17 Feb 2017.
- 18 Dec 2017 Planned initiation date changed from 1 Oct 2016 to 22 Nov 2016.